Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.
about
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design.TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalenceAn investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets.
P2860
Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Current methodology to assess ...... sodium products is inadequate.
@ast
Current methodology to assess ...... sodium products is inadequate.
@en
type
label
Current methodology to assess ...... sodium products is inadequate.
@ast
Current methodology to assess ...... sodium products is inadequate.
@en
prefLabel
Current methodology to assess ...... sodium products is inadequate.
@ast
Current methodology to assess ...... sodium products is inadequate.
@en
P356
P1433
P1476
Current methodology to assess ...... sodium products is inadequate.
@en
P2093
Vicky A Blakesley
P2860
P2888
P356
10.1208/AAPSJ070105
P407
P577
2005-03-30T00:00:00Z
P5875
P6179
1045524686